Evaxion A/S reports EIB debt conversion via Form 6-K filing

Rhea-AI Filing Summary

Evaxion A/S (NASDAQ: EVAX) filed a Form 6-K on 11 July 2025 to furnish a press release announcing that the Company has finalized an agreement with the European Investment Bank (EIB) to convert existing debt into equity. The press release, provided as Exhibit 99.1, is the only substantive disclosure contained in the filing. No additional terms, financial amounts, or timing details are included in the 6-K.

Positive

• Agreement reached with the European Investment Bank to convert debt into equity, which could influence Evaxion’s capital structure once full terms are disclosed.

Negative

• None.

Insights

Financial Analyst

TL;DR Limited disclosure: Evaxion reports a debt-to-equity conversion agreement with EIB; specifics and financial impact are not provided.

The filing merely furnishes a press release headline, so investors learn only that an agreement has been reached to convert debt into equity. While such transactions can improve balance-sheet flexibility, the absence of amounts, conversion ratio, and timing prevents any definitive assessment of dilution or leverage reduction. Until the full press release or additional filings outline concrete figures, the market impact remains indeterminate.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On July 11, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion finalizes agreement with EIB to convert debt into equity". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits 

Exhibit No.		Description
99.1		Evaxion finalizes agreement with EIB to convert debt into equity

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: July 11, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer

FAQ

What did Evaxion A/S (EVAX) announce in the July 11 2025 Form 6-K?

The company furnished a press release stating it has finalized an agreement with the EIB to convert debt into equity.

Is any financial detail about the EIB debt-to-equity conversion provided?

No. The 6-K references the agreement but does not include amounts, conversion ratios, or timing.

Where can investors find the complete press release?

The full press release is attached as Exhibit 99.1 to the Form 6-K filed on July 11 2025.

Does the filing mention how the conversion will affect existing shareholders?

No shareholder impact metrics or dilution estimates are included in this 6-K.

Which corporate officer signed the July 11 2025 Form 6-K for Evaxion?

Interim Chief Executive Officer Birgitte Rønø signed the filing.